
U.S. approval of the Alzheimer’s drug Aduhelm is already mired in controversy. Now a new study finds that most Alzheimer’s patients could not have taken part in clinical trials that led to the green light. In June, the U.S. Food and Drug Administration gave accelerated approval to Aduhelm (aducanumab) for treating patients with mild cognitive… read on > read on >